PFE - Ampio Pharmaceuticals Is Waking Up From Its COVID-19 Slumber Approaching Potential Approval For Severe OAK
Ampio Pharmaceuticals Inc. (AMPE) has had a long road to FDA approval for its osteoarthritis drug called Ampion. It's been 9 years and 5 clinical trials in the making, and they are in their final push for approval. There is clear evidence suggestive of approval for Ampion in osteoarthritis of the knee (OAK) due to the positive results in almost all their clinical trials. After completion of an ongoing final trial, Ampion may finally be able to cross the finish line to tap the large OAK market. In mid-March, the COVID-19 pandemic created